Genocea Biosciences, Inc.
GNCAQ
$0.00
$0.000.00%
OTC PK
| 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
|---|---|---|---|---|---|
| Net Income | 13.19% | 24.06% | 8.36% | 12.73% | -18.24% |
| Total Depreciation and Amortization | 36.24% | 59.29% | 10.96% | 4.41% | -8.27% |
| Total Amortization of Deferred Charges | 16.67% | 16.67% | 50.00% | 50.00% | 50.00% |
| Total Other Non-Cash Items | -653.68% | -650.17% | -123.76% | -863.63% | 61.70% |
| Change in Net Operating Assets | -31.29% | -28.88% | 47.23% | 331.76% | 449.89% |
| Cash from Operations | -19.72% | -8.93% | -7.10% | 6.11% | 2.38% |
| Capital Expenditure | 9.27% | -27.20% | -173.82% | -274.20% | -201.74% |
| Sale of Property, Plant, and Equipment | -53.16% | 166.67% | 25.45% | 43.14% | 23.44% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 8.25% | -25.56% | -180.08% | -286.22% | -212.28% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 82.23% | -11,267.91% | -12,518.02% | -2,164.35% | -1,153.07% |
| Issuance of Common Stock | -90.99% | -86.23% | -84.14% | 883.62% | 112.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -93.52% | -92.90% | -89.38% | 906.80% | 107.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -216.12% | -207.51% | -194.49% | 205.64% | 1,884.47% |